ATAI is supporting the revival of treatments with prior evidence in humans, such as psilocybin and ketamine, in fighting mental health disorders
Depression, anxiety, post-traumatic stress disorder, obsessive-compulsive disorder, bipolar disorder and other psychiatric conditions are increasingly becoming a burden for patients, families and societies.
We believe that
- using psychedelic compounds in therapy could provide an opportunity to significantly advance psychiatry
- treatment solutions should be as convenient, cost-effective and fast as possible
- clinical evidence has to meet the highest scientific standards
- fully integrated mental health solutions are the future